Nizar Issa, MD
Pulmonary Disease · Forrest City, ARNPI 1609096577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by GSK at 46.3% of the total.
Across 238 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$932
- Sunovion Pharmaceuticals Inc.$210
- Boehringer Ingelheim$208
- Mylan Specialty L.p.$206
- Viatris Specialty LLC$192
- plus $545 from 11 others
What the payments were for
- Food & beverage$4,23299%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 105 | $1,976 |
| AstraZeneca(2 entities) | 57 | $932 |
| Sunovion Pharmaceuticals Inc. | 17 | $210 |
| Boehringer Ingelheim | 14 | $208 |
| Mylan Specialty L.p. | 14 | $206 |
| Viatris Specialty LLC | 9 | $192 |
| Harmony Biosciences LLC | 5 | $160 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Philips North America LLC | 5 | $71 |
| Insmed, Inc. | 3 | $49 |
| Electromed, Inc. | 1 | $36 |
| Circassia Inc. | 2 | $28 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Pulmonx Corporation | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$125
- XYWAV$122
- TRELEGY ELLIPTA$120
How this compares
$4,269 in reported general payments places this provider in the 55th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 801 | $700,836 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 479 | $330,089 |
| Breo ElliptaFluticasone/Vilanterol | 174 | $91,653 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 97 | $73,074 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $53,604 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $19,082 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 17 | $12,534 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 470 | $10,631 |
| Ventolin HfaAlbuterol Sulfate | 98 | $5,722 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,264 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $5,136 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,987 |
| Fluticasone Propionate | 105 | $1,437 |
| Armodafinil | 12 | $727 |
| Ethambutol Hcl | 11 | $296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,976 | $1,127,8421,467 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $932 | $85,220148 claims |
| Boehringer IngelheimStiolto Respimat | $208 | $73,07497 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Forrest City
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
- Mark SiffordJonesboro$20K
- Zafirah SalmanNorth Little Rock$18K
- Dominika SzwedoNorth Little Rock$17K
- Hanan Khadam-MakhoulLittle Rock$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.